Anna Obenauf
@obenaufa.bsky.social
Group leader Research Institute of Molecular Pathology (IMP) impvienna.bsky.social in Vienna, trained at MSKCC, working on #cancer #tumorimmunology #resistance. Mentor. Mum. Views are my own.
https://www.obenauflab.com/
https://www.imp.ac.at/
https://www.obenauflab.com/
https://www.imp.ac.at/
Excited to present at the @metastasisresearch.bsky.social webinar soon. Registration is free!
October 13, 2025 at 7:14 PM
Excited to present at the @metastasisresearch.bsky.social webinar soon. Registration is free!
🔥Trio Fatale: Neutrophils, NETs and Necrosis
👉 authors.elsevier.com/a/1lk-k3qNrU...
We summarized for @cp-immunity.bsky.social
"Neutrophils drive vascular occlusion, tumour necrosis and metastasis" published in @nature.com by @megeblad.bsky.social @adrover.bsky.social rdcu.be/eFdau
Congrats!
👉 authors.elsevier.com/a/1lk-k3qNrU...
We summarized for @cp-immunity.bsky.social
"Neutrophils drive vascular occlusion, tumour necrosis and metastasis" published in @nature.com by @megeblad.bsky.social @adrover.bsky.social rdcu.be/eFdau
Congrats!
September 9, 2025 at 3:20 PM
🔥Trio Fatale: Neutrophils, NETs and Necrosis
👉 authors.elsevier.com/a/1lk-k3qNrU...
We summarized for @cp-immunity.bsky.social
"Neutrophils drive vascular occlusion, tumour necrosis and metastasis" published in @nature.com by @megeblad.bsky.social @adrover.bsky.social rdcu.be/eFdau
Congrats!
👉 authors.elsevier.com/a/1lk-k3qNrU...
We summarized for @cp-immunity.bsky.social
"Neutrophils drive vascular occlusion, tumour necrosis and metastasis" published in @nature.com by @megeblad.bsky.social @adrover.bsky.social rdcu.be/eFdau
Congrats!
Excited to be in Paris this week for a joint seminar at @institutcurie.bsky.social and @institutpasteur.bsky.social . Looking forward to connecting with colleagues—and to showing my 👧 the city!
September 9, 2025 at 11:07 AM
Excited to be in Paris this week for a joint seminar at @institutcurie.bsky.social and @institutpasteur.bsky.social . Looking forward to connecting with colleagues—and to showing my 👧 the city!
🇦🇹 Scientists in Austria: Don’t miss this chance to hear directly from @embo.org Director Fiona Watt about funding opportunities available. A great way to learn and connect with the community! @vbcscitraining.bsky.social @impvienna.bsky.social
May 20, 2025 at 8:05 AM
🇦🇹 Scientists in Austria: Don’t miss this chance to hear directly from @embo.org Director Fiona Watt about funding opportunities available. A great way to learn and connect with the community! @vbcscitraining.bsky.social @impvienna.bsky.social
Excited to be back at my home turf. Big thanks for inviting me to the 2025 DocDay at the MedUni Graz. It’s been a while since I attended the 1st Doc Day #blastfromthepast
February 13, 2025 at 5:01 PM
Excited to be back at my home turf. Big thanks for inviting me to the 2025 DocDay at the MedUni Graz. It’s been a while since I attended the 1st Doc Day #blastfromthepast
And another highlight by the @juliandownward.bsky.social lab Saptaparna Mukherjee focusing on the oncogenic cooperation of MYC and KRAS driving an ieTME.
February 11, 2025 at 1:32 PM
And another highlight by the @juliandownward.bsky.social lab Saptaparna Mukherjee focusing on the oncogenic cooperation of MYC and KRAS driving an ieTME.
Miriam Molina Arcas from the Downward lab is presenting their exciting work on how to engage the immune system in KRAS driven tumors @molinaarcas.bsky.social @juliandownward.bsky.social important concepts close to my ❤️
February 11, 2025 at 1:03 PM
Miriam Molina Arcas from the Downward lab is presenting their exciting work on how to engage the immune system in KRAS driven tumors @molinaarcas.bsky.social @juliandownward.bsky.social important concepts close to my ❤️
Piro Lito @mskcancercenter.bsky.social kicking off the #EACRBI_MAPK25 conference 🤩
February 11, 2025 at 12:14 PM
Piro Lito @mskcancercenter.bsky.social kicking off the #EACRBI_MAPK25 conference 🤩
Also check out www.opnme.com a very nice resource of @boehringerglobal.bsky.social for the entire scientific community.
February 11, 2025 at 12:09 PM
Also check out www.opnme.com a very nice resource of @boehringerglobal.bsky.social for the entire scientific community.
Starting now! EACR-Boehringer Ingelheim Conference on Drugging and Regulating the MAP Kinase Pathway @helloeacr.bsky.social @boehringerglobal.bsky.social Looking forward to two days of exciting science and engaging discussions!
February 11, 2025 at 12:06 PM
Starting now! EACR-Boehringer Ingelheim Conference on Drugging and Regulating the MAP Kinase Pathway @helloeacr.bsky.social @boehringerglobal.bsky.social Looking forward to two days of exciting science and engaging discussions!
Join us at #KSCancerImmune25 in Fairmont Banff Springs held jointly with Immune Cell Therapies. Register now:
www.keystonesymposia.org/conferences/...
See you on the slopes ⛷️ and in the sessions!
www.keystonesymposia.org/conferences/...
See you on the slopes ⛷️ and in the sessions!
January 6, 2025 at 11:07 PM
Join us at #KSCancerImmune25 in Fairmont Banff Springs held jointly with Immune Cell Therapies. Register now:
www.keystonesymposia.org/conferences/...
See you on the slopes ⛷️ and in the sessions!
www.keystonesymposia.org/conferences/...
See you on the slopes ⛷️ and in the sessions!
🌟Keystone Cancer Immunotherapy conference 2025 🌟 Speaker Highlight #2 at #KSCancerImmune25: Dr. Ton N. Schumacher @nkinl.bsky.social will discuss how T cells detect tumors in “Dissecting T Cell Recognition of Cancer.” Don’t miss his cutting-edge immunology insights!
January 6, 2025 at 11:07 PM
🌟Keystone Cancer Immunotherapy conference 2025 🌟 Speaker Highlight #2 at #KSCancerImmune25: Dr. Ton N. Schumacher @nkinl.bsky.social will discuss how T cells detect tumors in “Dissecting T Cell Recognition of Cancer.” Don’t miss his cutting-edge immunology insights!
Would love to see many of you at #KSCancerImmune25 at Fairmont Banff Springs, I am co-organizing together with Stefani Spranger & Christian Blank, held jointly with Immune Cell Therapies.
www.keystonesymposia.org/conferences/...
www.keystonesymposia.org/conferences/...
January 6, 2025 at 10:55 PM
Would love to see many of you at #KSCancerImmune25 at Fairmont Banff Springs, I am co-organizing together with Stefani Spranger & Christian Blank, held jointly with Immune Cell Therapies.
www.keystonesymposia.org/conferences/...
www.keystonesymposia.org/conferences/...
His work includes many groundbreaking discoveries, including this one www.science.org/doi/abs/10.1... Learn more about Dr. June’s pioneering work in Glioblastoma here www.forbes.com/sites/juerge...
January 6, 2025 at 10:55 PM
His work includes many groundbreaking discoveries, including this one www.science.org/doi/abs/10.1... Learn more about Dr. June’s pioneering work in Glioblastoma here www.forbes.com/sites/juerge...
🌟Keystone Cancer Immunotherapy conference 2025 🌟
#KSCancerImmune25 Speaker Highlight #1 Dr. Carl June, the father of CAR T-cell therapy and 2024 #BreakthroughPrize winner will share critical advances in cancer immunology in his talk “Cell Therapies: Current State of the Art”.
#KSCancerImmune25 Speaker Highlight #1 Dr. Carl June, the father of CAR T-cell therapy and 2024 #BreakthroughPrize winner will share critical advances in cancer immunology in his talk “Cell Therapies: Current State of the Art”.
January 6, 2025 at 10:55 PM
🌟Keystone Cancer Immunotherapy conference 2025 🌟
#KSCancerImmune25 Speaker Highlight #1 Dr. Carl June, the father of CAR T-cell therapy and 2024 #BreakthroughPrize winner will share critical advances in cancer immunology in his talk “Cell Therapies: Current State of the Art”.
#KSCancerImmune25 Speaker Highlight #1 Dr. Carl June, the father of CAR T-cell therapy and 2024 #BreakthroughPrize winner will share critical advances in cancer immunology in his talk “Cell Therapies: Current State of the Art”.
The kids are absolutely loving Prof. Bombasti at our annual Holiday Party! 😍 It’s such a joy to see them return year after year and watch them grow. @impvienna.bsky.social @vbcscitraining.bsky.social @viennabiocenter.bsky.social #WorkLifeIntegration
December 6, 2024 at 4:21 PM
The kids are absolutely loving Prof. Bombasti at our annual Holiday Party! 😍 It’s such a joy to see them return year after year and watch them grow. @impvienna.bsky.social @vbcscitraining.bsky.social @viennabiocenter.bsky.social #WorkLifeIntegration
18/23 Important insight: Continuous treatment with COX2 inhibitors is needed to maintain the permissive immune microenvironment. When treatment stops, tumors can quickly relapse - highlighting the dynamic nature of immune responses and the continuous requirement for a stimulatory TME ⚠️
November 27, 2024 at 5:58 PM
18/23 Important insight: Continuous treatment with COX2 inhibitors is needed to maintain the permissive immune microenvironment. When treatment stops, tumors can quickly relapse - highlighting the dynamic nature of immune responses and the continuous requirement for a stimulatory TME ⚠️
15/23 Based on these insights, we developed combination therapies targeting both pathways to improve the outcome of immunotherapies:
COX2 inhibitors (to block PGE2)
5-Azacitidine (to boost IFN-I)
Flt3L (to expand antigen-presenting cells)
COX2 inhibitors (to block PGE2)
5-Azacitidine (to boost IFN-I)
Flt3L (to expand antigen-presenting cells)
November 27, 2024 at 5:58 PM
15/23 Based on these insights, we developed combination therapies targeting both pathways to improve the outcome of immunotherapies:
COX2 inhibitors (to block PGE2)
5-Azacitidine (to boost IFN-I)
Flt3L (to expand antigen-presenting cells)
COX2 inhibitors (to block PGE2)
5-Azacitidine (to boost IFN-I)
Flt3L (to expand antigen-presenting cells)
14/23 Clinical relevance: Our findings help explain why NSAID use (which block PGE2 production) correlates with better immunotherapy responses in melanoma and lung cancer patients 🏥
November 27, 2024 at 5:58 PM
14/23 Clinical relevance: Our findings help explain why NSAID use (which block PGE2 production) correlates with better immunotherapy responses in melanoma and lung cancer patients 🏥
13/23 Blocking PGE2 production (through COX1/2 gene deletion) or restoring IFN-I signaling (through IRF3 and IRF7 overexpression) in resistant tumors was sufficient to restore T cell responses and tumor control, even without conventional type I dendritic cells! 💪
November 27, 2024 at 5:58 PM
13/23 Blocking PGE2 production (through COX1/2 gene deletion) or restoring IFN-I signaling (through IRF3 and IRF7 overexpression) in resistant tumors was sufficient to restore T cell responses and tumor control, even without conventional type I dendritic cells! 💪
12/23 In RTT tumors, high PGE2 and low IFN-I levels prevent monocytes from acquiring an inflammatory state. Instead, they differentiate into immunosuppressive macrophages that block anti-tumor immunity 🛑
November 27, 2024 at 5:58 PM
12/23 In RTT tumors, high PGE2 and low IFN-I levels prevent monocytes from acquiring an inflammatory state. Instead, they differentiate into immunosuppressive macrophages that block anti-tumor immunity 🛑
10/23 🐭➡️👤 In humans, we found macrophages in an analogous inflammatory state across different tumor entities! Similar to what we saw in our mouse models, these inflammatory macrophages (Cxcl9/10 high 📊) co-localize with activated CD8+ T cells in specialized tumor niches at the tumor border.
November 27, 2024 at 5:58 PM
10/23 🐭➡️👤 In humans, we found macrophages in an analogous inflammatory state across different tumor entities! Similar to what we saw in our mouse models, these inflammatory macrophages (Cxcl9/10 high 📊) co-localize with activated CD8+ T cells in specialized tumor niches at the tumor border.
9/23 Key finding: Inflammatory monocytes can stimulate T cells in tumors through "peptide MHCI cross-dressing" directly acquiring peptide-MHCI complexes from cancer cells to engage TCRs on CD8+ T cells. This mediates T cell restimulation even in the absence of cDCs! 🔬🤯
November 27, 2024 at 5:58 PM
9/23 Key finding: Inflammatory monocytes can stimulate T cells in tumors through "peptide MHCI cross-dressing" directly acquiring peptide-MHCI complexes from cancer cells to engage TCRs on CD8+ T cells. This mediates T cell restimulation even in the absence of cDCs! 🔬🤯
8/23 🤔 cDC1s are established players of anti-tumor immunity, but we wondered what role monocytes were playing in these immune hubs. Many monocytes were in a stimulatory state displaying high levels of IFN-stimulated genes (ISGs), IL-15 and Cxcl9/l10, thus we termed these “inflammatory monocytes” 🔥.
November 27, 2024 at 5:58 PM
8/23 🤔 cDC1s are established players of anti-tumor immunity, but we wondered what role monocytes were playing in these immune hubs. Many monocytes were in a stimulatory state displaying high levels of IFN-stimulated genes (ISGs), IL-15 and Cxcl9/l10, thus we termed these “inflammatory monocytes” 🔥.
7/23 👀❌ This crucial step of intratumoral T cell restimulation has been overlooked for many years, and only recently was incorporated in the last iteration of the cancer immunity cycle by Mellman and colleagues ♻️ www.cell.com/immunity/pdf...
November 27, 2024 at 5:58 PM
7/23 👀❌ This crucial step of intratumoral T cell restimulation has been overlooked for many years, and only recently was incorporated in the last iteration of the cancer immunity cycle by Mellman and colleagues ♻️ www.cell.com/immunity/pdf...